Ind-Swift Laboratories Limited
INDSWFTLAB
Rank in Stocks
#14453
Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the... Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, including macrolide antibiotics, cardiovascular ailments, antihistamines, antidiabetics, antipsychotics, bone resorption inhibitors, antimigraine treatments, Parkinson's disease, hyperparathyroidism, analgesics, aromatase inhibitors, nootropics, antidiarrhoeal/antiprotozoal conditions, anticholinergics, sedatives, hypnotics, alcohol abstinence, antineoplastics, and solutions for ADHD symptoms. Additionally, Ind-Swift supplies reference standards and impurities for a long list of specific compounds such as acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. Beyond its core manufacturing operations, the company offers a broad spectrum of services. These encompass early and late-phase drug development, process research and development, contract and API manufacturing, custom chemicals and synthesis, analytical development, regulatory support, specialized chemistry services, impurity profiling, isolation, discovery, identification, characterization, and project management. Founded in 1995, and headquartered in Manimajra, India, Ind-Swift Laboratories Limited also exports its products internationally.
Share Price
$3.72
Last synced: 2026-11-09
Market Cap
$323.10M
Change (1 day)
0.79%
Change (1 year)
220.90%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Ind-Swift Laboratories Limited (INDSWFTLAB)
Category
Healthcare
Operating Margin for Ind-Swift Laboratories Limited (INDSWFTLAB)
Operating Margin as of November 2026 TTM: 4.20%
According to Ind-Swift Laboratories Limited's latest financial reports, its current operating margin (TTM) is 4.20%. At the end of 2025 the company had an operating margin of -7.81%.
Operating Margin history for Ind-Swift Laboratories Limited from 2006 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 4.20% | -153.78% |
| 2025 | -7.81% | -149.81% |
| 2024 | 15.68% | 4.26% |
| 2023 | 15.04% | 68.99% |
| 2022 | 8.90% | -28.51% |
| 2021 | 12.45% | 32.73% |
| 2020 | 9.38% | 59.25% |
| 2019 | 5.89% | -4.85% |
| 2018 | 6.19% | -173.95% |
| 2017 | -8.37% | -35.96% |
| 2016 | -13.07% | -40.32% |
| 2015 | -21.90% | 46.78% |
| 2014 | -14.92% | 30.65% |
| 2013 | -11.42% | -290.65% |
| 2012 | 5.99% | -55.83% |
| 2011 | 13.56% | 7.02% |
| 2010 | 12.67% | -25.03% |
| 2009 | 16.90% | 5.56% |
| 2008 | 16.01% | 9.73% |
| 2007 | 14.59% | -8.70% |
| 2006 | 15.98% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -95.38% |
DE
|
|
| 19.68% | -95.31% |
DE
|
|
| 13.26% | -96.84% |
JP
|
|
| 17.08% | -95.93% |
CH
|
|
| 14.92% | -96.45% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Ind-Swift Laboratories Limited's operating margin
What is Ind-Swift Laboratories Limited's operating margin?
Ind-Swift Laboratories Limited's operating margin is 4.20%, as of Nov 2026.
What was Ind-Swift Laboratories Limited's operating margin in 2025?
In 2025, Ind-Swift Laboratories Limited's operating margin was -7.81%, compared with 15.68% in 2024.
How has Ind-Swift Laboratories Limited's operating margin changed since 2020?
From 2020 to 2025, Ind-Swift Laboratories Limited's operating margin was highest in 2024 (15.68%) and lowest in 2025 (-7.81%).
How does Ind-Swift Laboratories Limited's operating margin compare with similar companies?
Ind-Swift Laboratories Limited's operating margin (4.20%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.